The invention provides novel compositions for use in silencing K Ras gene expression. More particularly the invention provides novel asymmetrical interfering RNA molecules as inhibitors of K Ras expression and to pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal.